22 May Merck KGaA, Darmstadt, Germany, Signs Definitive Agreement to Acquire Mirus Bio for US$ 600 million
- Acquisition will advance Merck KGaA, Darmstadt, Germany, integrated offering for viral vector manufacturing
- Complements existing portfolio for development and production of novel modalities such as cell and gene therapies
- Novel modalities are a key growth area for company’s Life Science business sector
Merck KGaA, Darmstadt, Germany, a leading science and technology company, has signed a definitive agreement to acquire life science company Mirus Bio for US$ 600 million (around € 550 million). Based in Madison, Wisconsin, USA, Mirus Bio is a specialist in the development and commercialization of transfection reagents. Transfection reagents, such as Mirus Bio’s TransIT-VirusGEN®, are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for cell and gene therapies.
“This strategic acquisition is a further building block for accelerating growth in the break-through technologies of the future. As a leader in the production of viral vectors, our goal is to make the significant potential of cell and gene therapy available for patients worldwide,” said Belén Garijo, Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany. “As a leading science and technology company, we are well-positioned to support our Life Science customers across the biopharmaceutical industry to bring new curative treatments to market.”